B+
Bull case
25%
Probability
Target price
$41.00
Analysis reference price unavailable
Analysis 2026-10-11 · RankAlpha Sentiment Codex
KEQU
Kewaunee ScientificANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-10-11 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$26.00
Analysis reference price unavailable
Analysis 2026-10-11 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-11
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+58.0
Score
AI commentary
The stored company earnings exhibit confirms the weaker Q1 print, but the packet does not verify consensus surprise, analyst revisions, current post-release price reaction, options skew, short interest or sufficient social coverage. Zero-valued sentiment fields indicate unavailable measurements, not neutral readings. The deterministic directional prior is neutral; this remains a low-coverage monitoring view. [#SEC-8K-2026-09-09]
RankAlpha Sentiment Codex - 2026-10-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31catalystLab Products Group volume pressureHigh impact
Fiscal Q1 2027 sales fell 6.7% year over year and diluted EPS fell to $0.58 from $1.04. Lower manufacturing volumes in the Lab Products Group could continue to weigh on earnings. The date is an estimated review horizon, not an announced event. [#8-K-2026-09-09] [#SEC-8K-2026-09-09]
2027-01-31eventBacklog conversionHigh impact
Backlog rose to $169.0 million from $165.9 million sequentially but remained below $205.0 million a year earlier. Subsequent results could clarify whether orders convert into sales; the date is an estimated monitoring horizon. [#SEC-8K-2026-09-09]
2027-04-30catalystPortfolio breadth and operating efficiencyHigh impact
Nu Aire broadened the laboratory-products portfolio in fiscal 2026, while cost controls and operating efficiencies partly offset lower Q1 manufacturing volumes. Sustained earnings improvement remains unproven; the date is an estimated fiscal-year review horizon. [#SEC-8K-2026-06-23] [#SEC-8K-2026-09-09]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-11 • Updated nightlySource: Internal modelMethodology